Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate VaccineBRYANT, Kristina A; BLOCK, Stan L; BAKER, Sherryl A et al.Pediatrics (Evanston). 2010, Vol 125, Num 5, pp 866-875, issn 0031-4005, 10 p.Article

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccineJACKSON, Lisa A; GURTMAN, Alejandra; RICE, Kathryn et al.Vaccine. 2013, Vol 31, Num 35, pp 3585-3593, issn 0264-410X, 9 p.Article

Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditionsCHO, Bo-Hyun; STOECKER, Charles; LINK-GELLES, Ruth et al.Vaccine. 2013, Vol 31, Num 50, pp 6011-6021, issn 0264-410X, 11 p.Article

Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing scheduleRODGERS, Gail L; ESPOSITO, Susanna; THOMPSON, Allison et al.Vaccine. 2013, Vol 31, Num 42, pp 4765-4774, issn 0264-410X, 10 p.Article

The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7ACOOPER, David; XINHONG YU; SIDHU, Mohinder et al.Vaccine. 2011, Vol 29, Num 41, pp 7207-7211, issn 0264-410X, 5 p.Conference Paper

Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020LINK-GELLES, Ruth; TAYLOR, Thomas; MOORE, Matthew R et al.Vaccine. 2013, Vol 31, Num 22, pp 2572-2577, issn 0264-410X, 6 p.Article

Comparing Health Outcomes and Costs of General Vaccination with Pneumococcal Conjugate Vaccines in Sweden: A Markov ModelBY, Asa; SOBOCKI, Patrik; FORSGREN, Arne et al.Clinical therapeutics. 2012, Vol 34, Num 1, pp 177-189, issn 0149-2918, 13 p.Article

Evolving Role of 13-valent Pneumococcal Conjugate Vaccine in Clinical PracticeAZZARI, Chiara; MARTINON-TORRES, Federico; SCHMITT, Einz-Josef et al.The Pediatric infectious disease journal. 2014, Vol 33, Num 8, pp 858-864, issn 0891-3668, 7 p.Article

Economic evaluation of second generation pneumococcal conjugate vaccines in NorwayROBBERSTAD, Bjarne; FROSTAD, Carl R; AKSELSEN, Per E et al.Vaccine. 2011, Vol 29, Num 47, pp 8564-8574, issn 0264-410X, 11 p.Article

EVOLUTION OF THE EPIDEMIOLOGY OF PNEUMOCOCCAL DISEASE AMONG UTAH CHILDREN THROUGH THE VACCINE ERAAMPOFO, Krow; PAVIA, Andrew T; STOCKMANN, Chris R et al.The Pediatric infectious disease journal. 2011, Vol 30, Num 12, pp 1100-1103, issn 0891-3668, 4 p.Article

The Changing Epidemiology of Invasive Pneumococcal Disease at a Tertiary Children's Hospital Through the 7-valent Pneumococcal Conjugate Vaccine Era: A Case for Continuous SurveillanceAMPOFO, Krow; CHB, M. B; MASON, Edward O et al.The Pediatric infectious disease journal. 2012, Vol 31, Num 3, pp 228-234, issn 0891-3668, 7 p.Article

13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): A phase 3, open-label trialSILFVERDAL, Sven Arne; FLODMARK, Carl-Erik; ROMBO, Lars et al.Vaccine. 2013, Vol 31, Num 9, pp 1284-1292, issn 0264-410X, 9 p.Article

Policy Statement-Recommendations for the Prevention of Streptococcus pneumoniae Infections in Infants and Children: Use of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23)Pediatrics (Evanston). 2010, Vol 126, Num 1, pp 186-190, issn 0031-4005, 5 p.Article

Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in EnglandVAN HOEK, Albert Jan; SHEPPARD, Carmen L; ANDREWS, Nick J et al.Vaccine. 2014, Vol 32, Num 34, pp 4349-4355, issn 0264-410X, 7 p.Article

Changes in the incidence of Streptococcus pneumoniae bacteremia and its serotypes over 10 years in one hospital in South KoreaMIEY PARK; KIM, Han-Sung; KYU SUNG SHIN et al.Vaccine. 2014, Vol 32, Num 48, pp 6403-6407, issn 0264-410X, 5 p.Article